Analyst Rating Update on CTI BioPharma (CTIC)

CTI BioPharma (NASDAQ:CTIC) : 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on CTI BioPharma (NASDAQ:CTIC). Zacks Investment Research suggests a Buy with a rank of 2. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 3 Wall Street Analysts endorse the stock as a Sell with a rating of 3.67.

CTI BioPharma (NASDAQ:CTIC) : The consensus price target for CTI BioPharma (NASDAQ:CTIC) is $2.88 for the short term with a standard deviation of $3.01. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $5, however, the pessimist price target for the company is $1.

Company shares have received an average consensus rating of Hold for the current week

CTI BioPharma (NASDAQ:CTIC): stock turned positive on Tuesday. Though the stock opened at $0.351, the bulls momentum made the stock top out at $0.38 level for the day. The stock recorded a low of $0.3341 and closed the trading day at $0.3592, in the green by 14.39%. The total traded volume for the day was 2,687,744. The stock had closed at $0.314 in the previous days trading.

In an insider trading activity,The director officer (President and CEO) of Cti Biopharma Corp, Bianco James A sold 10,000 shares at $0.37 on June 24, 2016. The Insider selling transaction had a total value worth of $3,700. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.